Overview

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Status:
Not yet recruiting

Trial end date:
2032-10-01

Target enrollment:

Participant gender:

Summary

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)

Phase:

Phase 3

Details

Lead Sponsor:

Immunic AG

Treatments:

Calcium
Calcium, Dietary